BIOGNOSYS
26.10.2021 14:02:10 CEST | Business Wire | Press release
Indivumed, developer of the world’s leading discovery platform for precision oncology, and Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today that they are extending their strategic partnership to provide biopharma customers with immunopeptidomics insights for oncology drug discovery.
The partnership is driven by each company’s unique capabilities in omics research, with Biognosys bringing industry-leading mass spectrometry-based proteomics technology and solutions, and Indivumed providing high-quality samples and data as well as its multi-omics based AI discovery system, nRavel® .
The initial partnership established in December 2019 focused on enriching Indivumed’s IndivuType multi-omics cancer database with proteome-level data from thousands of samples analyzed by Biognosys. Since then, Indivumed and Biognosys have successfully collaborated on various clinical research projects and published results from a large-scale study in lung cancer at AACR 2020 , revealing new biomarkers for tumor biology. Building on this success, the companies are now extending their partnership with immunopeptidomics research.
Immunopeptides play an essential role in the immune system and can be analyzed to support the development of personalized treatments, especially in cancers, vaccines, infectious, and autoimmune diseases. Mass spectrometry is currently the only technology that can reliably measure and identify immunopeptide profiles of biological samples on a large scale.
Biognosys’ immunopeptidomics workflow deploys its patented Hyper Reaction Monitoring (HRM™) mass spectrometry technology for proteome quantification in combination with its proprietary Spectronaut™ and SpectroMine™ data analysis software to identify over 10,000 unique immunopeptides from low amounts of sample material. The workflow is highly efficient and scalable for use in large-scale clinical studies.
Indivumed then can provide biopharma customers further validation and insights on the immunopeptide signatures identified through Biognosys’ workflow, based on its IndivuType, global multi-omics cancer database and its analytics platform nRavel® to enhance R&D activities and new discovery programs for individualized therapy.
Biognosys will present validation of the workflow sensitivity and reproducibility at the American Society of Mass Spectrometry (ASMS) Annual Conference on Nov 1st in Philadelphia, while Indivumed will present clinically relevant multi-omic analysis at the BioData World Congress on Nov 2nd in Basel.
The new immunopeptidomics offering is already being applied successfully with third party biopharma companies to enhance their drug discovery efforts.
Lukas Reiter, PhD, Chief Technology Officer of Biognosys states: “Biognosys’ HRM™ technology uniquely addresses key challenges in immunopeptidomics research. Using only small amounts of tissue, our optimized workflow provides deep and comprehensive biological insights on the immune system. We are thrilled to apply this solution on the valuable tissue samples from Indivumed and support drug discovery in areas of high unmet need.”
Roald Forsberg, Chief Business Officer and Head of IndivuType Business Unit at Indivumed commented: “With our unique IndivuType database and our nRavel® AI system we have a fantastic opportunity to make new discoveries regarding the role of the immune response in the tumor microenvironment and to develop new immunotherapies against cancer. This extended partnership with Biognosys gives us the ability to validate and expand our findings using state-of-the-art mass-spectrometry technology which will accelerate our path towards bringing these discoveries into the practice of personalized oncology.”
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The Company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com .
About Indivumed
Driven by our mission to unveil the complex mechanisms of cancer and to advance precision oncology, Indivumed combines the world’s most comprehensive multi-omics data with extensive medical experience, bioinformatics expertise, and AI-integrated advanced analytics. Our global clinical network enables us to collect and analyze thousands of patient samples using a standardized approach to ensure biospecimen quality across three business units – IndivuServ, IndivuTest, and IndivuType. The unparalleled depth and quality of our data – coupled with our robust product and service offerings – gives us the ability to obtain novel insights and accelerate cancer research. For more information, visit www.indivumed.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005054/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetApp Data Platform Powers Data Operations for Super Bowl LX27.1.2026 14:00:00 CET | Press release
Intelligent Data Infrastructure Elevates the Fan Experience at Levi’s® Stadium NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced that it is powering data operations for Super Bowl LX. As the Official Intelligent Data Infrastructure Partner of the San Francisco 49ers and the National Football League (NFL), NetApp provides the enterprise-grade data platform that powers the digital and physical experiences for football fans, whether watching the game from Levi’s® Stadium or from their couch on the other side of the world. “The world runs on data, even in an industry as physical as sports,” said Gabie Boko, Chief Marketing Officer at NetApp. “Optimizing data for innovation isn’t just about where the data lives, but also about how it moves. There is no place where that will be on display more clearly than Levi’s® Stadium during the Super Bowl. While the stadium is not a traditional data center, during a game, it transforms into an interactive data center b
REVEAL GENOMICS Aligns Founder Leadership With Priorities to Support Long-term Growth, Scientific Excellence, and Global Partnerships27.1.2026 13:43:00 CET | Press release
The company appoints Joel Parker, Ph.D., as Chief Scientific Officer; Ana Vivancos, Ph.D., as Director of NGS and Genomic Technologies; and Aleix Prat, M.D., Ph.D., as Chairman of the Board of Directors.Leadership roles are assumed by the company’s co-founders, who strengthen governance and alignment across scientific, clinical, and strategic priorities.The strengthened leadership framework supports global scientific progress and clinical adoption of the genomic assays of REVEAL GENOMICS. REVEAL GENOMICS, a Barcelona-based biotechnology company that advances precision oncology through biomarker innovation, today announced a strengthened leadership framework with several senior appointments. These appointments underscore the company’s commitment to scientific excellence, technological rigor, and clinical impact, and they seek to support the continued development, validation, and global adoption of the company’s genomic assays. This press release features multimedia. View the full releas
Bial Achieves Key Milestone in Phase 2b ACTIVATE Study of BIA 28-6156 in GBA1-Associated Parkinson’s Disease27.1.2026 12:00:00 CET | Press release
75% of patients have completed the Week 78 Last Study VisitTopline results expected in mid-2026 Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced that 75% of patients currently enrolled in its ongoing Phase 2b clinical study ACTIVATE (ClinicalTrials.gov identifier: NCT05819359) have completed the double-blind treatment period through week 78. This operational milestone represents a significant step toward the completion of the ACTIVATE study, which is evaluating the efficacy, safety, tolerability, pharmacodynamics, and pharmacokinetics of BIA 28-6156 in patients with Parkinson’s disease (PD) who have a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). The date of the Last Patient, Last Visit (LPLV) is anticipated in April 2026, with topline results on track to be released in mid-2026. “We look forward to presenting data from our Phase 2b study. BIA 28-6156 is the leading asset in GBA-PD, and clinical out
Libraesva and Cyber Guru Announce Strategic Combination to Create a Leading European Human-Centric Cybersecurity Provider27.1.2026 11:00:00 CET | Press release
The combination of two Italian cybersecurity leaders with strong international footprints creates a unique European player delivering an integrated portfolio of Email Security and Security Awareness Training to reduce human cyber risk end-to-end. Cyber Guru and Libraesva today announced a strategic combination that brings together two highly complementary Italian cybersecurity companies to form a new European leader in human-centric cyber protection. The combined group will offer organisations an integrated approach to defending against email-based threats, social engineering, and human-targeted attacks, integrating advanced technology with behavioural resilience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127531600/en/ Cyber threats are evolving rapidly, with attackers focusing less on infrastructure and more on the weak link in security – human behaviour. Phishing, business email compromise, smishing, QR-code attack
Europe’s First Meteorological Infrared Sounder Reveals the Atmosphere in 3D27.1.2026 10:30:00 CET | Press release
The first images from Europe’s pioneering meteorological infrared sounder were unveiled today at the EU Space Conference in Brussels, marking a major advance in the ability to monitor how the atmosphere evolves before and during severe weather. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127490399/en/ Full Earth disc image from the MTG-S Infrared Sounder showing a surface-temperature-sensitive channel, captured between 12:45 and 15:30 UTC on 15 November 2025. The image distinguishes land and sea surface temperatures as well as cloud-top temperatures, highlighting cloud structures and weather systems. Hot desert regions appear in red, while cold cloud tops are shown in blue. © Image: Data acquired on 15 November 2025 and processed by industrial partners Thales and OHB under the supervision of EUMETSAT and ESA. Visual produced by EUMETSAT. The images were captured by the Infrared Sounder (IRS) flying aboard Meteosat Thir
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom